CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性硬化症的治疗进展：新型疗法（免疫检查点抑制剂、CAR-T、Anti-CD40L）
英文原题：Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).
查看英文原题
Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
随着多发性硬化（MS）患者年龄增长，癌症风险也随之增加。免疫检查点抑制剂（ICIs）是新型单克隆抗体，已彻底改变了癌症治疗。然而，其使用受到免疫相关不良事件的限制。对于患有MS和已有自身免疫性疾病的患者，人们担心使用ICIs可能会恶化疾病结局。在本综述的第一部分，我们讨论了关于ICIs和MS的当前数据，这些数据总体上表明，从MS疾病活动的角度来看，它们耐受性良好。我们建议MS不应成为使用ICIs的严格禁忌症，这应取决于个体化的风险获益讨论。在第二部分，我们聚焦于MS的新型疗法，包括CAR-T 细胞和抗CD40L治疗。这些较新的疗法有潜力解决MS中未满足的需求，因为它们可以穿过血脑屏障，并有可能靶向可能导致进展型MS病理生理学的区室化中枢神经系统炎症。
展开英文摘要原文
As patients with multiple sclerosis (MS) age, the risk of cancer also increases. Immune checkpoint inhibitors (ICIs) are novel monoclonal antibodies that have revolutionized cancer treatment.
However, their use is limited by immune related adverse events. In patients with MS and pre-existing autoimmune disease there is concern that use of ICIs could worsen disease outcome. In the first part of this review we discuss the current data on ICIs and MS which overall suggest that they are well tolerated from the standpoint of MS disease activity.
We recommend that MS not be a strict contraindication to ICI use which should depend on an individualized risk benefit discussion. In the second part, we focus on novel therapies for MS including CAR-T cell and anti-CD40L treatments. These newer therapies have the potential to address an unmet need in MS as they can cross the blood-brain and have the potential to target compartmentalized central nervous inflammation that may underly the pathophysiology of progressive MS.
论文信息
- 作者
- Conway SE、Galetta K
- 单位
- Brigham and Women's Hospital, Boston, MA, USA. Electronic address: seconway@bwh.harvard.edu.United States
- 文献类型
- 综述
- 期刊
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025 Jul
- 原文标识
- PubMed 40021418 · DOI 10.1016/j.neurot.2025.e00558
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →